Prognosis of Relapsing Neuromyelitis Optica
نویسندگان
چکیده
منابع مشابه
Neuromyelitis Optica
An 11-year-old girl developed sudden visual loss in her left eye, preceding subacute myelitis by 9 months. Multifocal lesions in the central nervous system were demonstrated by magnetic resonance imaging. Although unilateral blindness is unusual, the clinical findings predominantly involving the optic nerve and spinal cord were consistent with the diagnosis of neuromyelitis optica (NMO). This c...
متن کاملTreatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
BACKGROUND To review our experience using methotrexate as a single long-term immunosuppressant (IS) therapy in neuromyelitis optica/neuromyelitis optica spectrum disorders (NMO/NMOSD). METHODS We performed a retrospective chart review of all patients with a diagnosis of NMO/NMOSD, supported by a positive NMO-IgG testing, who were treated with methotrexate. A paired sample 2 tailed t test was ...
متن کاملImmunotherapy of Neuromyelitis Optica
Neuromyelitis optica (NMO) is a chronic inflammatory disease of the central nervous system that affects the optic nerves and spinal cord resulting in visual impairment and myelopathy. There is a growing body of evidence that immunotherapeutic agents targeting T and B cell functions, as well as active elimination of proinflammatory molecules from the peripheral blood circulation, can attenuate d...
متن کاملIlluminating neuromyelitis optica pathogenesis.
W hat is the most important moment in the history of a disease? Let us consider neuromyelitis optica (NMO), which was coined by French neurologist Eugene Devic in 1894 for a disease believed until recently to be a subtype of multiple sclerosis (MS). The discovery (in 2004) of a disease-specific biomarker for NMO revolutionized our understanding of both NMO and MS (1). In PNAS, Hinson et al. (2)...
متن کاملTreatment in Neuromyelitis Optica
Background: The effects of interferon1b (IFN1b ) administration in multiple sclerosis (MS) patients have been confirmed, however, those in neuromyelitis optica (NMO) patients have not been shown. In this study, we assessed the effects of IFN1b treatment on disease exacerbation and disability progression in MS or NMO patients. Methods: We reviewed a series of 104 consecutive patients with relaps...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pediatric Neurology Briefs
سال: 2003
ISSN: 2166-6482,1043-3155
DOI: 10.15844/pedneurbriefs-17-3-7